vs
吉利德科学（GILD）与美国再保险集团（RGA）财务数据对比。点击上方公司名可切换其他公司
吉利德科学的季度营收约是美国再保险集团的1.2倍（$7.9B vs $6.6B），吉利德科学净利率更高（27.5% vs 7.0%，领先20.6%），美国再保险集团同比增速更快（26.6% vs 4.7%），过去两年吉利德科学的营收复合增速更高（8.9% vs 2.3%）
吉利德科学是总部位于美国加利福尼亚州福斯特城的生物制药企业，专注于研发抗病毒药物，覆盖艾滋病、乙型肝炎、丙型肝炎、流感、新冠等治疗领域，核心产品包括来迪派韦索磷布韦、索磷布韦等，现为纳斯达克100指数及标普100指数成分股。
美国再保险集团（RGA）是总部位于美国密苏里州大圣路易斯地区西郊切斯特菲尔德的全球人寿与健康再保险控股集团。截至2024年12月31日，集团有效人寿再保额约3.9万亿美元，总资产达1187亿美元，是全球唯一主营人寿及健康相关再保险业务的国际企业。
GILD vs RGA — 直观对比
营收规模更大
GILD
是对方的1.2倍
$6.6B
营收增速更快
RGA
高出21.9%
4.7%
净利率更高
GILD
高出20.6%
7.0%
两年增速更快
GILD
近两年复合增速
2.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $7.9B | $6.6B |
| 净利润 | $2.2B | $463.0M |
| 毛利率 | 79.5% | — |
| 营业利润率 | 25.0% | 7.7% |
| 净利率 | 27.5% | 7.0% |
| 营收同比 | 4.7% | 26.6% |
| 净利润同比 | 22.4% | 212.8% |
| 每股收益（稀释后） | $1.75 | $6.91 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GILDRGA
| Q4 25 | $7.9B | $6.6B | ||
| Q3 25 | $7.8B | $6.2B | ||
| Q2 25 | $7.1B | $5.6B | ||
| Q1 25 | $6.7B | $5.3B | ||
| Q4 24 | $7.6B | $5.2B | ||
| Q3 24 | $7.5B | $5.7B | ||
| Q2 24 | $7.0B | $4.9B | ||
| Q1 24 | $6.7B | $6.3B |
净利润GILDRGA
| Q4 25 | $2.2B | $463.0M | ||
| Q3 25 | $3.1B | $253.0M | ||
| Q2 25 | $2.0B | $180.0M | ||
| Q1 25 | $1.3B | $286.0M | ||
| Q4 24 | $1.8B | $148.0M | ||
| Q3 24 | $1.3B | $156.0M | ||
| Q2 24 | $1.6B | $203.0M | ||
| Q1 24 | $-4.2B | $210.0M |
毛利率GILDRGA
| Q4 25 | 79.5% | — | ||
| Q3 25 | 79.8% | — | ||
| Q2 25 | 78.8% | — | ||
| Q1 25 | 76.9% | — | ||
| Q4 24 | 79.1% | — | ||
| Q3 24 | 79.1% | — | ||
| Q2 24 | 77.8% | — | ||
| Q1 24 | 76.8% | — |
营业利润率GILDRGA
| Q4 25 | 25.0% | 7.7% | ||
| Q3 25 | 42.8% | 5.2% | ||
| Q2 25 | 34.9% | 6.1% | ||
| Q1 25 | 33.6% | 7.0% | ||
| Q4 24 | 32.4% | 4.3% | ||
| Q3 24 | 11.8% | 3.8% | ||
| Q2 24 | 38.0% | 5.5% | ||
| Q1 24 | -64.6% | 4.3% |
净利率GILDRGA
| Q4 25 | 27.5% | 7.0% | ||
| Q3 25 | 39.3% | 4.1% | ||
| Q2 25 | 27.7% | 3.2% | ||
| Q1 25 | 19.7% | 5.4% | ||
| Q4 24 | 23.6% | 2.8% | ||
| Q3 24 | 16.6% | 2.8% | ||
| Q2 24 | 23.2% | 4.2% | ||
| Q1 24 | -62.4% | 3.3% |
每股收益（稀释后）GILDRGA
| Q4 25 | $1.75 | $6.91 | ||
| Q3 25 | $2.43 | $3.81 | ||
| Q2 25 | $1.56 | $2.70 | ||
| Q1 25 | $1.04 | $4.27 | ||
| Q4 24 | $1.43 | $2.21 | ||
| Q3 24 | $1.00 | $2.33 | ||
| Q2 24 | $1.29 | $3.03 | ||
| Q1 24 | $-3.34 | $3.16 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $68.0M | $4.2B |
| 总债务越低越好 | $24.9B | $5.7B |
| 股东权益账面价值 | $22.7B | $13.5B |
| 总资产 | $59.0B | $156.6B |
| 负债/权益比越低杠杆越低 | 1.10× | 0.42× |
8季度趋势，按日历期对齐
现金及短期投资GILDRGA
| Q4 25 | $68.0M | $4.2B | ||
| Q3 25 | $19.0M | $4.6B | ||
| Q2 25 | $69.0M | $5.4B | ||
| Q1 25 | — | $5.2B | ||
| Q4 24 | — | $3.3B | ||
| Q3 24 | — | $5.2B | ||
| Q2 24 | — | $4.6B | ||
| Q1 24 | — | $5.9B |
总债务GILDRGA
| Q4 25 | $24.9B | $5.7B | ||
| Q3 25 | $24.9B | $5.7B | ||
| Q2 25 | $24.9B | $5.7B | ||
| Q1 25 | $25.0B | $5.7B | ||
| Q4 24 | $26.7B | $5.0B | ||
| Q3 24 | $23.2B | $5.1B | ||
| Q2 24 | $23.3B | $5.1B | ||
| Q1 24 | $25.2B | $4.4B |
股东权益GILDRGA
| Q4 25 | $22.7B | $13.5B | ||
| Q3 25 | $21.5B | $13.0B | ||
| Q2 25 | $19.7B | $12.1B | ||
| Q1 25 | $19.2B | $11.4B | ||
| Q4 24 | $19.3B | $10.8B | ||
| Q3 24 | $18.5B | $11.1B | ||
| Q2 24 | $18.3B | $9.7B | ||
| Q1 24 | $17.5B | $9.5B |
总资产GILDRGA
| Q4 25 | $59.0B | $156.6B | ||
| Q3 25 | $58.5B | $152.0B | ||
| Q2 25 | $55.7B | $133.5B | ||
| Q1 25 | $56.4B | $128.2B | ||
| Q4 24 | $59.0B | $118.7B | ||
| Q3 24 | $54.5B | $120.3B | ||
| Q2 24 | $53.6B | $109.9B | ||
| Q1 24 | $56.3B | $106.0B |
负债/权益比GILDRGA
| Q4 25 | 1.10× | 0.42× | ||
| Q3 25 | 1.16× | 0.44× | ||
| Q2 25 | 1.27× | 0.48× | ||
| Q1 25 | 1.30× | 0.50× | ||
| Q4 24 | 1.38× | 0.47× | ||
| Q3 24 | 1.26× | 0.46× | ||
| Q2 24 | 1.28× | 0.52× | ||
| Q1 24 | 1.44× | 0.47× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.3B | $7.3B |
| 自由现金流经营现金流 - 资本支出 | $3.1B | — |
| 自由现金流率自由现金流/营收 | 39.4% | — |
| 资本支出强度资本支出/营收 | 2.6% | — |
| 现金转化率经营现金流/净利润 | 1.52× | 15.83× |
| 过去12个月自由现金流最近4个季度 | $9.5B | — |
8季度趋势，按日历期对齐
经营现金流GILDRGA
| Q4 25 | $3.3B | $7.3B | ||
| Q3 25 | $4.1B | $-990.0M | ||
| Q2 25 | $827.0M | $-820.0M | ||
| Q1 25 | $1.8B | $-1.4B | ||
| Q4 24 | $3.0B | $17.1B | ||
| Q3 24 | $4.3B | $-1.1B | ||
| Q2 24 | $1.3B | $-967.0M | ||
| Q1 24 | $2.2B | $-5.7B |
自由现金流GILDRGA
| Q4 25 | $3.1B | — | ||
| Q3 25 | $4.0B | — | ||
| Q2 25 | $720.0M | — | ||
| Q1 25 | $1.7B | — | ||
| Q4 24 | $2.8B | — | ||
| Q3 24 | $4.2B | — | ||
| Q2 24 | $1.2B | — | ||
| Q1 24 | $2.1B | — |
自由现金流率GILDRGA
| Q4 25 | 39.4% | — | ||
| Q3 25 | 51.0% | — | ||
| Q2 25 | 10.2% | — | ||
| Q1 25 | 24.8% | — | ||
| Q4 24 | 37.4% | — | ||
| Q3 24 | 55.2% | — | ||
| Q2 24 | 17.2% | — | ||
| Q1 24 | 31.6% | — |
资本支出强度GILDRGA
| Q4 25 | 2.6% | — | ||
| Q3 25 | 1.9% | — | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 1.6% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 1.9% | — | ||
| Q2 24 | 1.9% | — | ||
| Q1 24 | 1.6% | — |
现金转化率GILDRGA
| Q4 25 | 1.52× | 15.83× | ||
| Q3 25 | 1.35× | -3.91× | ||
| Q2 25 | 0.42× | -4.56× | ||
| Q1 25 | 1.34× | -5.00× | ||
| Q4 24 | 1.67× | 115.81× | ||
| Q3 24 | 3.44× | -6.84× | ||
| Q2 24 | 0.82× | -4.76× | ||
| Q1 24 | — | -27.31× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GILD
| Other | $3.4B | 43% |
| HIV Products Biktarvy | $3.3B | 41% |
| HIV Products Odefsey | $239.0M | 3% |
| Liver Disease Products Other Liver Disease | $170.0M | 2% |
| HIV Products Other HIV | $155.0M | 2% |
| Other Products Yescarta | $150.0M | 2% |
| Liver Disease Products Vemlidy | $149.0M | 2% |
| Liver Disease Products Sofosbuvir Velpatasvir | $140.0M | 2% |
| HIV Products Symtuza Revenue Share | $98.0M | 1% |
| Veklury | $80.0M | 1% |
| Cell Therapy Products Tecartus | $32.0M | 0% |
| Royalty Contract And Other | $22.0M | 0% |
RGA
暂无分部数据
